Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
423.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 3.00 (0.71%)
Market Cap: £208.04m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Year-End Trading Update

21 Jan 2020 07:00

RNS Number : 3793A
Zotefoams PLC
21 January 2020
 

Zotefoams plc

("Zotefoams" or "Group" or "the Company")

 

Year-End Trading Update

 

 

21st January 2020 - Zotefoams, a world leader in cellular materials technology, today provides a trading update following the Company's financial year end on 31 December 2019.

 

Trading conditions in the final quarter were largely as anticipated with the result that full year Group revenue will be at a similar level to 2018. For the financial year, business units performed as follows:

 

·; c20% increase in High Performance Products ("HPP") sales;

·; c60% increase in MuCell Extrusion LLC ("MEL") sales and;

·; c10% decline in Polyolefin sales, reflecting challenging market conditions in the second half of the year.

In the final quarter of the year profitability was ahead of management expectations prior to an adverse impact from foreign exchange rate movements. From the date of our last announcement on 3 October until 31 December 2019 sterling appreciation resulted in an adverse foreign exchange impact, for this period alone, on Group profit before tax of £0.8m. Of this, £0.6m related to the non-cash translation impact of intra-group loans. The Group therefore expects to report, subject to audit, adjusted profit before tax and exceptional item* for the year ended 31 December 2019 of approximately £9.1m.

 

All major capital projects were either completed during the year or are expected to complete in 2020 on time and on budget.

 

The Company expects to announce preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

While market conditions during the year have been challenging for our Polyolefins business, we expect to see a recovery in 2020. In line with our long-term strategy we expect to deliver further growth in our HPP and MEL business units.

 

Due to the current market conditions, recently commissioned long-term capacity investments are expected to run at low utilisation rates, with depreciation and other costs being under recovered in the short term. These investments are consistent with the opportunity and ambition of Zotefoams and, with the anticipated recovery in the markets for Polyolefin foams and further growth from HPP, we expect improved utilisation of these assets in the latter part of 2020.

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Zach Cohen

 

 

 

 

 

* Profit before tax, exceptional item and the amortisation of acquired intangible assets

 

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKZGZMNGMGGZM
Date   Source Headline
13th Apr 20212:06 pmRNSDirector/PDMR Shareholding
12th Apr 20214:09 pmRNSDirector/PDMR Shareholding
25th Mar 20211:26 pmRNSDirector/PDMR Shareholding
23rd Mar 20213:19 pmRNSCorrection: Preliminary Results
23rd Mar 20217:00 amRNSPreliminary Results
12th Mar 20212:53 pmRNSDirector/PDMR Shareholding
10th Mar 20211:12 pmRNSHolding(s) in Company
9th Mar 20213:13 pmRNSHolding(s) in Company
9th Mar 20213:05 pmRNSHolding(s) in Company
9th Mar 20211:55 pmRNSHolding(s) in Company
8th Mar 20213:04 pmRNSResult of secondary placing in Zotefoams plc
8th Mar 202112:00 pmRNSProposed secondary placing in Zotefoams plc
8th Mar 20217:00 amRNSNotice of results and investors presentation
5th Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Feb 20217:00 amRNSProduction starts at new £23m plant in Poland
15th Feb 20217:00 amRNSPolish factory virtual tour and investor Q&A
12th Feb 20214:20 pmRNSDirector/PDMR Shareholding - Replacement
12th Feb 20213:54 pmRNSDirector/PDMR Shareholding
12th Feb 20213:38 pmRNSDirector/PDMR Shareholding
8th Feb 20214:41 pmRNSSecond Price Monitoring Extn
8th Feb 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSOperational and Trading Update
12th Jan 20213:50 pmRNSDirector/PDMR Shareholding
14th Dec 20204:19 pmRNSDirector/PDMR Shareholding
12th Nov 20203:40 pmRNSDirector/PDMR Shareholding
5th Nov 20207:00 amRNSOperational and Trading Update
22nd Oct 202010:36 amRNSDirector/PDMR Shareholding
14th Oct 20207:00 amRNSDirector/PDMR Shareholding
9th Oct 20207:00 amRNSDirector/PDMR Shareholding
7th Oct 20207:00 amRNSExternal Auditor Appointment
1st Oct 20204:13 pmRNSDirector/PDMR Shareholding
16th Sep 20204:29 pmRNSDirector/PDMR Shareholding
11th Sep 20204:41 pmRNSSecond Price Monitoring Extn
11th Sep 20204:35 pmRNSPrice Monitoring Extension
9th Sep 20205:51 pmRNSHolding(s) in Company
1st Sep 20204:40 pmRNSSecond Price Monitoring Extn
1st Sep 20204:35 pmRNSPrice Monitoring Extension
18th Aug 202010:54 amRNSDirector/PDMR Shareholding
12th Aug 20203:52 pmRNSDirector/PDMR Shareholding
11th Aug 20207:00 amRNSInterim Results
14th Jul 20207:00 amRNSDirector/PDMR Shareholding
9th Jul 20204:35 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSNotice of Results
16th Jun 20205:05 pmRNSHolding(s) in Company
12th Jun 20203:25 pmRNSDirector/PDMR Shareholding
8th Jun 20202:06 pmRNSResult of the 2020 Annual General Meeting
2nd Jun 20208:00 amRNSOperational and Trading Update
22nd May 202012:07 pmRNSSecond Price Monitoring Extn
22nd May 202012:02 pmRNSPrice Monitoring Extension
14th May 20203:48 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.